ArticleJournal for immunotherapy of cancer2021
T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Humanized anti-CD33 CAR-T cells and antibody-drug conjugates for targeted therapy in acute myeloid leukemia.Frontiers in medicine · 2026Article
- A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia.Blood cancer journal · 2025Article
- Unveiling the potential of CLL-1: a promising target for AML therapy.Biomarker research · 2025Review
- Immune-related adverse events of antibody-based biological medicines in cancer therapy.Journal of cellular and molecular medicine · 2024Review
- Article
- Druggable targets for the immunopathy of Alzheimer's disease.RSC medicinal chemistry · 2023Review
- Diagnosis and management of adult central nervous system leukemia.Blood science (Baltimore, Md.) · 2023Review
- Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells.Journal of visualized experiments : JoVE · 2023Article
- Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.Frontiers in immunology · 2023Article
- Identification and validation of a siglec-based and aging-related 9-gene signature for predicting prognosis in acute myeloid leukemia patients.BMC bioinformatics · 2022Article
- Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy.Journal for immunotherapy of cancer · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAcute myeloid leukemia (AML) remains one of the most challenging hematological malignancies. Despite progress in therapeutics, majority of patients succumb to this neoplasm. CD33 is a proven therapeutic target, given its expression on most AML cells. Almost all anti-CD33 antibodies target the membrane distal immunoglobulin V (IgV) domain of the CD33 extracellular domain.
methodsIn this manuscript, we present data on three bispecific antibodies (BsAbs) against the CD33 IgV and membrane proximal immunoglobulin C (IgC) domains. We use in vitro binding and cytotoxicity assays to show the effect of these BsAbs on AML cell lines. We also use immunodeficient mice-bearing leukemias from cell lines and patient-derived xenografts to show the effect of these BsAbs in vivo.
resultsIn vitro, the IgV-targeting BsAb had higher binding to AML cell lines using flow cytometry and delivered more potent cytotoxicity in T-cell-dependent cytotoxicity assays; importantly, the IgC domain-targeting outperformed the IgV domain-targeting BsAb in medullary and extramedullary leukemia animal models.
conclusionsThese data support further clinical development of this BsAb for first-in-human phase I clinical trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.